Survey on Real-World Interventions and Strategies for Treat-to-Target Approaches in Psoriasis Management in Canada - Top-Institutions - MDSpire

Survey on Real-World Interventions and Strategies for Treat-to-Target Approaches in Psoriasis Management in Canada

  • By

  • Jensen Yeung

  • Parbeer Grewal

  • Perla Lansang

  • Ron Vender

  • Marni Wiseman

  • Rami Abou Zeinab

  • Maxime Barakat

  • Vimal H. Prajapati

  • April 16, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    University of Toronto
    University of Toronto

    Toronto, ON

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

  • #2

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Translational Medicine

  • #3

    Massachusetts General Hospital (MGH) Dermatology
    Massachusetts General Hospital (MGH) Dermatology

    Boston, MA

    Key Differentiators

    • Dermatology
    • Clinical Trials
    • Psoriasis Research

  • #4

    University of British Columbia
    University of British Columbia

    Vancouver, BC

    Key Differentiators

    • Dermatology
    • Clinical Research
    • Patient Outcomes

  • #5

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Dermatology
    • Immunodermatology
    • Clinical Research

Original Source(s)

Survey on Real-World Interventions and Strategies for Treat-to-Target Approaches in Psoriasis Management in Canada

  • by Jensen Yeung, Parbeer Grewal, Perla Lansang, Ron Vender, Marni Wiseman, Rami Abou Zeinab, Maxime Barakat, Vimal H. Prajapati

  • April 16, 2026

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Coordinated Care Strategies for Psoriasis: An Organized Method for Timely Identification and Referral of Comorbid Conditions

FDA Approves New Oral Option for Plaque Psoriasis

Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.